What is Melanotan I? Structure, research and status

Melanotan I is the research name for afamelanotide, an alpha-MSH analog first tested for tanning and now approved only as Scenesse for a rare disorder.

Complete guide10 min read

Key takeaway

Melanotan I and afamelanotide are two names for the same 13-amino-acid peptide, alpha-MSH with two amino acid swaps. Small trials in the 1990s and 2000s found that it darkened the skin of healthy volunteers. Clinuvel developed it as Scenesse, approved in the EU in 2014 and by the FDA in 2019 for adults with erythropoietic protoporphyria (EPP). Neither the FDA nor the EU has approved it for cosmetic tanning.

At a glance

Article typeComplete guide
Regulatory statusNot FDA-approved“No product sold under the name melanotan I is approved by the FDA.” (this article)
ClassSkin & cosmetic
Body systemsSkin & connective tissue
Studies cited7 in this article · 7 across 1 article on Melanotan I
Related productsCopper peptides and melanocortin fragments

Melanotan 1, also written melanotan I or MT-I, is a synthetic peptide that University of Arizona researchers tested to darken skin without sunlight. The same molecule later became afamelanotide, the active ingredient in Scenesse. Products sold online under the melanotan name are a separate matter, and regulators have warned that their contents and safety are unknown.

Quick answer: Melanotan I is the research name for afamelanotide, a melanocortin receptor agonist that raises dark skin pigment. In the US and EU, its only approved form is Scenesse, a prescription drug for adults with EPP. No product sold under the name melanotan I is approved by the FDA. It is a different peptide from melanotan II.

Vitrapep does not sell Melanotan I; this page is a reference summary of published research and regulatory information.

What is Melanotan I?

Melanotan I is a linear peptide of 13 amino acids. PubChem files it under the name afamelanotide, with the sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 [1]. Table 1 lists its other names.

The molecule is alpha-melanocyte stimulating hormone (alpha-MSH) with two changes. Norleucine replaces methionine at position 4, and the mirror-image form of phenylalanine sits at position 7. For background on amino acid chains, see what peptides are.

Sawyer, Hruby, Hadley and colleagues described the analog in 1980 [2]. In frog skin and mouse melanoma cell tests, it resisted serum enzymes and was 26 times as potent as alpha-MSH in one assay [2].

Hadley and Dorr, of the University of Arizona, later wrote that two analogs from this work reached clinical testing [3]. Linear melanotan I was tested for tanning and cyclic melanotan II for erectile dysfunction. Clinuvel Pharmaceuticals later ran trials under the code CUV1647 (NCT00472901) and the name afamelanotide.

Table 1

What is Melanotan I

FactDetail
Other namesAfamelanotide; melanotan-1; MT-1; NDP-MSH; [Nle4, D-Phe7]-alpha-MSH; CUV1647 [1]
StructureLinear peptide of 13 amino acids; alpha-MSH with norleucine at position 4 and D-phenylalanine at position 7 [1], [7]
Molecular formulaC78H111N21O19 [1]
Molecular weight1646.8 g/mol [1]
CAS number75921-69-6 [1]
ClassMelanocortin receptor agonist that binds mainly to the MC1 receptor [7]
First described1980, by Sawyer, Hruby, Hadley and colleagues [2]
Approved productScenesse (Clinuvel): EU, December 22, 2014; FDA, October 8, 2019 [8], [9]
WADA 2026 listNot named [14]

How does Melanotan I work?

The Scenesse label states that afamelanotide "is a melanocortin receptor agonist and binds predominantly to MC1-R" [7]. MC1 receptors sit on melanocytes, the pigment-making cells of the skin. The label adds that it raises eumelanin, the brown-black pigment, "independently of exposure to sunlight or artificial UV light sources" [7].

Human skin biopsy data fit that description. In a 2000 study of seven volunteers, forearm eumelanin rose 98% one week after treatment ended (Dorr et al., 2000). Pheomelanin, the red-yellow pigment, did not change significantly. The study had no control group.

In laboratory work, a 2026 mouse study described NDP-MSH as a pan-melanocortin receptor agonist (Zhang et al., 2026). Its cyclic relative has its own melanotan II complete guide.

What did the early tanning studies show?

The first human tests aimed at a tan without sun exposure. Most were small, short and run by the Arizona group that made the peptide.

Levine and colleagues ran a randomized, double-blind, placebo-controlled trial in 28 healthy white men [4]. Both poor and good tanners darkened with the peptide, and no one on placebo darkened. All participants used a high-potency sunscreen. Peak darkening came 1 to 3 weeks after treatment ended [4].

In 2004, Dorr and colleagues reported three open-label phase 1 studies that paired the peptide with UV-B light or sunlight [5]. Back tanning was stronger and lasted at least three weeks longer than with sunlight alone. Sunlight-only controls needed 50% more sun exposure for an equivalent tan [5].

Barnetson and colleagues in Sydney compared the peptide with placebo; 65 fair-skinned volunteers completed the three-month trial [6]. Melanin density rose 41% in people with sun-sensitive skin and 12% in those with less sensitive skin. In the sensitive group, sunburn cells after a UV test fell by more than half. Thymine dimers, a form of UV damage to DNA, fell 59% [6].

Table 2

What did the early tanning studies show

StudyDesign and sizeMain findingSide effects reportedEvidence level
Levine et al., 1991 [4]Randomized, double-blind, placebo-controlled; 28 healthy white menSkin darkened in both tanning groups; none darkened on placeboNot described in the abstractHuman, small
Ugwu et al., 1997Crossover pharmacokinetic study; 3 menForehead, arm and neck tanning, still present 3 weeks laterOccasional stomach upset, facial flushingHuman, very small
Dorr et al., 2000Uncontrolled; 7 volunteers with skin types III or IVForearm eumelanin up 98%; pheomelanin unchangedNot described in the abstractHuman, very small
Dorr et al., 2004 [5]Three open-label phase 1 studies with UV-B or sunlight; 28 volunteers in totalTan stronger and longer lasting than with sunlight aloneNausea, transient facial flushingHuman, small
Barnetson et al., 2006 [6]Placebo-controlled; 65 fair-skinned volunteers completed 3 monthsMelanin density up 41% (sensitive skin) and 12% (less sensitive); fewer sunburn cellsNot described in the abstractHuman, surrogate end points

These results describe pigment changes in healthy volunteers. None of the studies was large or long enough to define rare or delayed harms.

What is Melanotan I approved for?

As afamelanotide, the peptide has one approved use in the United States. Its label says Scenesse is indicated "to increase pain free light exposure" in adults with past phototoxic reactions from erythropoietic protoporphyria (EPP) [7]. EPP is a rare disorder in which light exposure causes severe pain [9], [10].

Drugs@FDA lists the original approval of NDA 210797 on October 8, 2019, as a new molecular entity with priority review [8]. The European Commission authorized Scenesse on December 22, 2014, under exceptional circumstances, for prevention of phototoxicity in adults with EPP [9].

Two randomized, double-blind, placebo-controlled EPP trials were reported together in 2015 [10]. In the 94-patient US trial, median pain-free time in direct sunlight was 69.4 hours with afamelanotide and 40.8 with placebo (P=0.04). That trial ran six months; the 74-patient EU trial ran nine, with medians of 6.0 and 0.8 hours (P=0.005) [10]. The afamelanotide complete guide covers these trials in detail.

On November 18, 2026, ClinicalTrials.gov listed 23 studies with afamelanotide as an intervention, in conditions such as vitiligo, xeroderma pigmentosum and stroke. A phase 3 vitiligo trial (NCT06109649) is listed as active, not recruiting, with no results posted. See how to find a peptide clinical trial for what registry statuses mean.

What side effects have been reported?

The early tanning studies enrolled few people. A three-person 1997 study described "occasional gastrointestinal upset and facial flushing" (Ugwu et al., 1997). The 2004 studies reported nausea and transient facial flushing, with no abnormal findings at sun-exposed skin sites [5].

The Scenesse label gives controlled data from 244 adults with EPP: 125 received Scenesse and 119 a vehicle [7]. It carries no boxed warning. Selected adverse reactions from the label:

Table 3

What side effects have been reported

Adverse reaction (Scenesse label)Scenesse, 125 adultsVehicle, 119 adults
Implant site reaction21%10%
Nausea19%14%
Oropharyngeal pain7%5%
Cough6%3%
Fatigue6%3%
Skin hyperpigmentation4%0%
Melanocytic nevus (mole)4%2%

The label also lists two warnings. Serious hypersensitivity reactions, including anaphylaxis, have been reported after approval [7]. The drug may darken existing moles and freckles, and the label recommends full body skin examinations to monitor pigmented lesions [7].

These figures describe the regulated drug, not products sold online as melanotan I.

How are unlicensed melanotan products different?

Tanning products sold online as "melanotan" are not Scenesse. A 2010 review described unregulated melanotan I or II products obtained online and through tanning salons and gyms (Langan et al., 2010). It noted UK regulator concern about impurity and blood-borne virus spread through shared needles.

In August 2008, the Danish Medicines Agency warned against a product called Melanotan sold online [12]. The agency said its effect and side effects had not been investigated. It added that the product was not licensed in Denmark, Europe or the United States, a statement made before the Scenesse approvals [12].

In an April 2024 response about melanotan II, the UK MHRA said the contents of unauthorized medicines are unknown (MHRA, 2024). It said there are no safeguards for their quality, safety or effectiveness. It also said it had "repeatedly taken action to remove Melanotan products from the market" for more than 10 years.

A 2017 review found growing numbers of case reports linking unregulated melanotan I and II use to changes in existing moles [11]. Reports also described new, sometimes dysplastic, moles. The review counted four reports of melanoma arising from existing moles during or shortly after use. The authors said conclusive evidence of a link is lacking [11]. Case reports cannot show cause or frequency.

Product quality is another unknown. In a 2026 laboratory stress study, afamelanotide broke down under every condition tested, forming 14 degradation products (Chawathe and Sharma, 2026). That study did not test products sold online. See research peptides and human-use risks for the broader issues.

What is the regulatory status of Melanotan I?

United States. An openFDA search of Drugs@FDA on November 18, 2026, found one approved product containing afamelanotide: Scenesse [8]. A search for "melanotan" returned no approved product. Vitrapep keeps a list of FDA-approved peptide medicines.

FDA's page on bulk drug substances that may present significant safety risks names melanotan II, citing published case reports that include melanoma [13]. The page, current as of April 22, 2026, does not name melanotan I or afamelanotide. That absence is not evidence of safety, since the page covers substances proposed for compounding.

European Union. Scenesse is authorized for adults with EPP [9]. EMA notes that it is no longer an orphan medicine after its removal from the orphan register in December 2024 [9].

Sport. The WADA 2026 Prohibited List does not name melanotan I or afamelanotide [14]. See the guide to the 2026 WADA list for the peptides it names.

Research use. NDP-MSH is still a laboratory tool. In the 2026 mouse study, it reduced urine protein loss and kidney damage in a membranous nephropathy model (Zhang et al., 2026). A research-use-only label does not make a product an approved drug or make use in people legal or safe.

What is still unknown about Melanotan I?

The tanning studies were small and short [4], [5], [6]. They measured pigment, sunburn cells and DNA damage markers, so they cannot show whether a peptide-induced tan changes skin cancer risk.

The melanoma question is open. Case reports describe changing moles and melanoma after unregulated melanotan use, but the 2017 review found no conclusive evidence of a link [11]. Without controlled data, the size of any risk is unknown. For the approved drug, phase 3 vitiligo results have not been posted.

Frequently asked questions

Is Melanotan I the same as afamelanotide?

Yes. PubChem lists melanotan I and melanotan-1 as synonyms for afamelanotide, the official name used for the approved drug.

Is Melanotan I the same as melanotan II?

No. Melanotan I is a linear peptide of 13 amino acids, while melanotan II is a shorter cyclic peptide. FDA lists melanotan II among bulk substances that may present significant safety risks.

Is Melanotan I approved for tanning?

No. Scenesse, the approved form of afamelanotide, is indicated only for adults with EPP and a history of phototoxic reactions.

Does Melanotan I need sunlight to darken skin?

No. The Scenesse label says afamelanotide raises eumelanin independently of sunlight or artificial UV light. In the 1991 trial, men using a high-potency sunscreen still darkened.

What side effects were reported with Melanotan I?

Early tanning studies reported nausea, facial flushing and stomach upset. The Scenesse label lists implant site reactions, nausea and skin darkening, and warns of serious hypersensitivity reactions.

Is there an approved dose of Melanotan I for tanning?

No. Neither the FDA nor the EU has approved it for tanning, so no regulator-reviewed tanning dose exists. See why research peptides have no dose.

What to know now

  • Melanotan I is the research name for afamelanotide, a 13-amino-acid alpha-MSH analog.
  • Small trials showed skin darkening in healthy volunteers but did not measure skin cancer.
  • Its only US and EU approval is Scenesse, for adults with EPP.
  • Danish and UK regulators have warned about unlicensed melanotan products.

What we’re watching

  • Posted results from the phase 3 vitiligo trial NCT06109649.
  • Any FDA label change for Scenesse covering new conditions or ages.
  • Further regulator action on unlicensed melanotan tanning products.

More for skin & connective tissue

All 26 compounds for skin & connective tissue

Sources: National Center for Biotechnology Information 2026; Sawyer 1980, Proceedings of the National Academy of Sciences of the United States of America, 77; Hadley 2006, Peptides, 27; Levine 1991, JAMA, 266; Dorr 2004, Archives of Dermatology, 140; Barnetson 2006, Journal of Investigative Dermatology, 126; Clinuvel 2024; U.S. Food and Drug Administration 2026; European Medicines Agency 2026; Langendonk 2015, New England Journal of Medicine, 373; Habbema 2017, International Journal of Dermatology, 56; Danish Medicines Agency 2008; U.S. Food and Drug Administration 2026; World Anti-Doping Agency 2025. All 14 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 16197727, afamelanotide. https://pubchem.ncbi.nlm.nih.gov/compound/16197727
  2. Sawyer, T. K., Sanfilippo, P. J., Hruby, V. J., Engel, M. H., Heward, C. B., Burnett, J. B., & Hadley, M. E. (1980). 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proceedings of the National Academy of Sciences of the United States of America, 77(10), 5754-5758. https://doi.org/10.1073/pnas.77.10.5754
  3. Hadley, M. E., & Dorr, R. T. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 27(4), 921-930. https://doi.org/10.1016/j.peptides.2005.01.029
  4. Levine, N., Sheftel, S. N., Eytan, T., Dorr, R. T., Hadley, M. E., Weinrach, J. C., Ertl, G. A., Toth, K., McGee, D. L., & Hruby, V. J. (1991). Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA, 266(19), 2730-2736. https://pubmed.ncbi.nlm.nih.gov/1658407/
  5. Dorr, R. T., Ertl, G., Levine, N., Brooks, C., Bangert, J. L., Powell, M. B., Humphrey, S., & Alberts, D. S. (2004). Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Archives of Dermatology, 140(7), 827-835. https://doi.org/10.1001/archderm.140.7.827
  6. Barnetson, R. S., Ooi, T. K., Zhuang, L., Halliday, G. M., Reid, C. M., Walker, P. C., Humphrey, S. M., & Kleinig, M. J. (2006). Nle4-D-Phe7-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. Journal of Investigative Dermatology, 126(8), 1869-1878. https://doi.org/10.1038/sj.jid.5700317
  7. Clinuvel, Inc. (2024). SCENESSE (afamelanotide) prescribing information (revised August 2024). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48
  8. U.S. Food and Drug Administration. (2026). Drugs@FDA: NDA 210797, SCENESSE. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210797
  9. European Medicines Agency. (2026). Scenesse (afamelanotide): EPAR. https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse
  10. Langendonk, J. G., Balwani, M., Anderson, K. E., et al. (2015). Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine, 373(1), 48-59. https://doi.org/10.1056/NEJMoa1411481
  11. Habbema, L., Halk, A. B., Neumann, M., & Bergman, W. (2017). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology, 56(10), 975-980. https://doi.org/10.1111/ijd.13585
  12. Danish Medicines Agency. (2008). Warning against the product Melanotan. https://laegemiddelstyrelsen.dk/en/pharmacies/medicines-imported-from-abroad/warnings-against-products/warning-against-the-product-melanotan/
  13. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  14. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026 (in effect January 1, 2026). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf